| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 8.701 | 8.884 | 8.390 | 8.400 | 8.412 | 8.389 | 8.355 | 8.421 | 8.400 | 8.393 |
| Total Income - EUR | 11.480 | 44.670 | 9.241 | 8.410 | 8.412 | 8.389 | 8.366 | 8.421 | 8.411 | 8.394 |
| Total Expenses - EUR | 19.007 | 57.552 | 5.372 | 3.599 | 3.477 | 3.455 | 3.477 | 4.571 | 5.731 | 4.334 |
| Gross Profit/Loss - EUR | -7.527 | -12.882 | 3.869 | 4.811 | 4.934 | 4.935 | 4.889 | 3.851 | 2.680 | 4.060 |
| Net Profit/Loss - EUR | -7.872 | -14.222 | 3.592 | 4.559 | 4.682 | 4.702 | 4.643 | 3.603 | 2.256 | 3.375 |
| Employees | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Farmacia Myosotis Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 90.234 | 38.892 | 35.389 | 32.380 | 29.463 | 26.922 | 24.425 | 22.595 | 20.626 | 18.621 |
| Current Assets | 21.317 | 5.631 | 4.899 | 3.039 | 9.267 | 11.233 | 11.705 | 9.854 | 12.331 | 15.212 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 570 | 1.215 | 31 | 80 | 126 | 171 | 239 | 425 | 450 | 522 |
| Cash | 20.746 | 4.416 | 4.868 | 2.960 | 9.141 | 11.062 | 11.466 | 9.429 | 11.881 | 14.690 |
| Shareholders Funds | 107.861 | 27.486 | 30.613 | 34.609 | 38.621 | 37.997 | 36.052 | 34.440 | 32.751 | 33.108 |
| Social Capital | 2.137 | 2.115 | 2.080 | 2.041 | 2.002 | 1.964 | 1.920 | 1.926 | 1.921 | 1.910 |
| Debts | 3.689 | 17.037 | 9.676 | 810 | 109 | 158 | 78 | 106 | 206 | 725 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4773 - 4773" | |||||||||
| CAEN Financial Year |
4773
|
|||||||||
Comments - Farmacia Myosotis Srl